Literature DB >> 1867958

A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine.

Q Y Yue1, J O Svensson, F Sjöqvist, J Säwe.   

Abstract

1. The kinetics of codeine and metabolites were studied in eight unrelated healthy Chinese subjects following a single oral dose of 50 mg codeine phosphate. The data were compared with those from eight Caucasian subjects who were matched with the Chinese group according to their metabolic ratio (MR) of debrisoquine. 2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h). Thus plasma clearance was significantly lower (P less than 0.02) and the plasma half-life was longer (P less than 0.05) in the Chinese. 3. Partial clearance by glucuronidation was significantly lower (0.79 +/- 0.14 s.d. vs 1.42 +/- 0.48 s.d. 1 h-1 kg-1) in Chinese than in Caucasians. 4. The total urinary recovery of drug-related material in 48 h urine was similar in Chinese (82.2%) and Caucasians (84.4%). The recovery of unchanged codeine was significantly higher in Chinese (5.7%) than in Caucasians (3.3%). 5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese. The corresponding ratios in Caucasians were 1:15, 50:1 and 6:1. 6. There was no significant difference between Chinese and Caucasians in the renal clearances of codeine and its primary metabolites. 7. Large interethnic differences in the kinetics of codeine have been shown. The Chinese are less able to metabolise codeine mainly because of a lower efficiency in glucuronidation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867958      PMCID: PMC1368573          DOI: 10.1111/j.1365-2125.1991.tb05586.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites.

Authors:  H H Zhou; R P Koshakji; D J Silberstein; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1989-03-02       Impact factor: 91.245

2.  Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese.

Authors:  Q Y Yue; L Bertilsson; M L Dahl-Puustinen; J Säwe; F Sjöqvist; I Johansson; M Ingelman-Sundberg
Journal:  Lancet       Date:  1989-10-07       Impact factor: 79.321

3.  Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease.

Authors:  D R Guay; W M Awni; J W Findlay; C E Halstenson; P A Abraham; J A Opsahl; E C Jones; G R Matzke
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

4.  Polymorphic O-demethylation of codeine.

Authors:  Z R Chen; A A Somogyi; F Bochner
Journal:  Lancet       Date:  1988-10-15       Impact factor: 79.321

5.  Low frequency of slow debrisoquine hydroxylation in a native Chinese population.

Authors:  Y C Lou; L Ying; L Bertilsson; F Sjöqvist
Journal:  Lancet       Date:  1987-10-10       Impact factor: 79.321

6.  Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

Authors:  M S Lennard; J H Silas; A J Smith; G T Tucker
Journal:  J Chromatogr       Date:  1977-03-11

7.  Interindividual and interethnic differences in the demethylation and glucuronidation of codeine.

Authors:  Q Y Yue; J O Svensson; C Alm; F Sjöqvist; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

8.  Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.

Authors:  Q Y Yue; J O Svensson; C Alm; F Sjöqvist; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

9.  Differences in diazepam pharmacokinetics in Chinese and white Caucasians--relation to body lipid stores.

Authors:  C R Kumana; I J Lauder; M Chan; W Ko; H J Lin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.

Authors:  Y Horai; M Nakano; T Ishizaki; K Ishikawa; H H Zhou; B I Zhou; C L Liao; L M Zhang
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

View more
  7 in total

1.  Ethnicity and adverse drug reactions.

Authors:  Erik Eliasson
Journal:  BMJ       Date:  2006-05-20

Review 2.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

3.  Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.

Authors:  Sijie Lu; R A Nand; J S Yang; Gang Chen; A S Gross
Journal:  Eur J Clin Pharmacol       Date:  2017-11-27       Impact factor: 2.953

Review 4.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?

Authors:  V Ozdemir; J Fourie; U Busto; C A Naranjo
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

6.  Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.

Authors:  Zoe E Barter; Geoffrey T Tucker; Karen Rowland-Yeo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

7.  Drug dosing error with drops: severe clinical course of codeine intoxication in twins.

Authors:  Maren Hermanns-Clausen; Wolfgang Weinmann; Volker Auwärter; Nerea Ferreirós; Rainer Trittler; Christoph Müller; Andreas Pahl; Andrea Superti-Furga; Roland Hentschel
Journal:  Eur J Pediatr       Date:  2008-10-21       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.